ADC Therapeutics SA is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
The company stated in the following press release that they use animals for product testing.
“ADCT-602 is an ADC that incorporates a pyrrolobenzodiazepine (PBD) drug linker and targets CD22, which is a clinically validated ADC target. Preclinical studies have demonstrated that ADCT-602 has significant anti-tumor activity in a number of animal models.” Read the following article
ADC Therapeutics is a commercial-stage biotechnology company dedicated to delivering next-generation PBD-based ADCs for those affected by cancer. With a deep understanding of ADC technology and of the oncology treatment landscape, ADC Therapeutics intends to address significant unmet medical needs and improve outcomes for those with difficult-to-treat cancers.
Company Website: https://www.adctherapeutics.com